Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Ototoxicity × Clear all

Phase

Status

Completed 9 Recruiting 5 Not yet recruiting 3 Unknown 2 Withdrawn 1 Suspended 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 375 Neoplasms 263 Carcinoma, Non-Small-Cell Lung 207 Prostatic Neoplasms 203 Colorectal Neoplasms 140 Lung Neoplasms 134 Pancreatic Neoplasms 121 Neoplasm Metastasis 120 Leukemia, Myeloid, Acute 119 Carcinoma, Hepatocellular 109 Multiple Myeloma 106 Lymphoma 98 Melanoma 91 Head and Neck Neoplasms 88 Ovarian Neoplasms 87 Brain Neoplasms 85 Recurrence 82 Leukemia, Lymphocytic, Chronic, B-Cell 77 Leukemia 77 Glioblastoma 73 Colonic Neoplasms 70 Squamous Cell Carcinoma of Head and Neck 67 Precursor Cell Lymphoblastic Leukemia-Lymphoma 67 Lymphoma, Non-Hodgkin 63 Carcinoma, Renal Cell 61 Lymphoma, Follicular 57 Hematologic Neoplasms 57 Lymphoma, Large B-Cell, Diffuse 56 Rectal Neoplasms 54 Stomach Neoplasms 50

Interventions

Dexamethasone 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02382068 2017-11-09

Dexamethasone in Preventing Hearing Loss in Patients Receiving Cisplatin

Ohio State University Comprehensive Cancer Center

Phase NA Withdrawn

Ototoxicity, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡